Sunday, April 1, 2018

FDA requires a warning on Gadolinium Contrast Agents

The U.S. Food and Drug Administration (FDA) has issued a new advisory requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) regarding gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs which may be linked to renal harm.   These agents have been associated with nephrogenic systemic fibrosis in patients with pre-existing renal failure.  Although this complication is rare, it is serious enough to justify the advisory to all professionals and patients.

Although the benefit of all approved GBCAs continues to outweigh any potential risks the FDA now requires several actions to alert health care professionals and patients about gadolinium retention after an MRI using a GBCA, including actions that can minimize problems.  Health care professionals should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium. These patients include those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. FDA suggests fewer repeated GBCA imaging studies when possible, particularly closely spaced MRI studies. However, physicians are advised to not avoid or defer necessary GBCA MRI scans.
Patients, parents, and caregivers should carefully read the new patient Medication Guide that will be given to him before receiving a GBCA. The Medication Guide explains the risks associated with GBCAs.  It also asks the patient to inform health care professional about medical conditions, such as: pregnancy, date of last MRI and number of prior MRI with gadolinium and kidney problems.

All new patients will be provided with the Medical Guide that provides educational information that every patient will be asked to read before receiving a GBCA. FDA will also require manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents.

Thursday, March 1, 2018

Thrombectomy 6 to 16 Hours After Ictus Is Beneficial

A paper by Albers et al published in the NEJM suggests that many more stroke victims can be saved from disability or death if they undergo removal of thrombi obstructing their internal carotid or proximal middle cerebral artery.

182 stroke patients with clots in major vessels were enrolled in the study.  They were last known to be well between 6 and 16 hours earlier and had diffusion and perfusion MRI scans upon admission to Emergency Room. Patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion, and an initial infarct size of less than 70 ml, and a ratio of the volume of ischemic tissue on perfusion imaging to infarct volume of 1.8 or more were randomly assigned to endovascular therapy plus standard medical therapy or standard medical therapy alone. The primary outcome was the score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability) at day 90.  Ninety-two of these patients had clots removed, while the remaining 90 did not. 

The study found that the 90-day death rate was lower for patients who had a thrombectomy vs. those who did not – 14 percent vs. 26 percent.   The data also indicated that more pronounced was the rate of functional independence among the thrombectomy patients – 45 percent vs. 17 percent at 90 days after the procedure.


Endovascular thrombectomy for ischemic stroke plus standard medical therapy resulted in better functional outcomes than standard medical therapy alone among patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion and a region of tissue that was ischemic but not yet infarcted.

Thursday, February 1, 2018

MRI safe for most patients with Pacemakers or Defibrillators

A study by Russo et al published in the NEJM found that MRI scans for patients with older not FDA approved pacemakers and implantable cardioverter-defibrillators (ICD) are safe even if the scan focuses on the chest area.

The researchers performed 1000 MRI in which patients had a pacemaker and in 500 MRI in which patients had an ICD in a 1.5T MRI scanner. No deaths, lead failures, losses of capture, or ventricular arrhythmias occurred during MRI. One ICD generator could not be interrogated after MRI and required immediate replacement; the device had not been appropriately programmed per protocol before the MRI.  Nine of the implants were disrupted but reset themselves to backup mode.  In all but one instance the effect was temporary.

Neither MRI performed on chest or in other parts of the body produced significant complications.   The concerns of potential magnetic field–induced cardiac lead heating, which could result in myocardial thermal injury and/or disrupt pacing properties of the devices were noted in this study.


The authors concluded that in their study, device or lead failure did not occur in any patient who was appropriately screened, and had the device reprogrammed in accordance with the pre-specified protocol.

Monday, January 1, 2018

Top Three

In the past four years I uploaded 113 posts in Radiology Weekly.  The top three in order of viewing frequency were:

Risk of Stroke due to Intracranial Atherosclerosis


iPad is Accurate in the Diagnosis of Bone Fractures


Circulating Tumor Cells Culture Promises Individualized Testing and Treatment 


Most visitors to my blog were from United States, Greece, Russia, France, South Korea, Poland, Ukraine, Turkey, United Kingdom, and Ireland in that order.  

I am sure some of you have noticed that since January 1st 2017 I post on the 1st of each month only. 

I wish you all and your families a Happy New Year.


Friday, December 1, 2017

American Women Prefer Annual Mammograms

The US Preventive ServicesTask Force (USPSTF) reaffirmed its recommendations to screen women ages 50-74 for breast cancer every two years stating that the harms of annual screening outweighed the benefits.  It also says the decision on frequency of screening should be individualized for women ages 40-49 based on risk.  The USPSTF found insufficient evidence to recommend for or against screening for women 75 or older.

Several professional societies like the American College of Radiology and Society of Breast Imaging advocate annual screening mammography starting at age 40.

A survey of 731 women indicated that 71% of the women who were 59 years old on average said they’d prefer a screening mammogram every year. Only 17% of participants felt having biennial screening would cause less anxiety. Of the patients who reported a prior abnormal mammogram, 13% believe biennial screening would cause less anxiety

The study was presented at the 103th annual meeting of the Radiological Society of North America.